Ephedra: Experts Speak Out On The Good, The Bad And The Ugly
This article was originally published in The Tan Sheet
Executive Summary
Left to its own devices FDA might not conduct a new risk/benefit analysis; however, a citizen petition asking for an analysis of an herb could spur FDA to action, Attorney Marc Ullman told "The Tan Sheet."
You may also be interested in...
NPA To Supreme Court: Risk-Benefit Standard Would “Unravel” DSHEA
The National Products Association filed a brief with the Supreme Court April 6 in support of Nutraceutical Corp.'s petition for review of an appellate court decision upholding FDA's use of a risk-benefit standard to determine product adulteration
NPA To Supreme Court: Risk-Benefit Standard Would “Unravel” DSHEA
The National Products Association filed a brief with the Supreme Court April 6 in support of Nutraceutical Corp.'s petition for review of an appellate court decision upholding FDA's use of a risk-benefit standard to determine product adulteration
NPA To Supreme Court: Risk-Benefit Standard Would “Unravel” DSHEA
The National Products Association filed a brief with the Supreme Court April 6 in support of Nutraceutical Corp.'s petition for review of an appellate court decision upholding FDA's use of a risk-benefit standard to determine product adulteration